Results of a phase 1 trial have shown promising antitumor activity of tazemetostat in patients with refractory B-cell non-Hodgkin lymphoma (both EZH2 mutated and non-mutated) [25]. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.